Ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS) or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer
New diagnosis of DCIS without invasive cancer; date of diagnosis defined as the date of the first pathology report that diagnosed the patient with DCIS
ADH/borderline DCIS
No previous history of breast cancer (DCIS or invasive cancer) in either breast prior to current DCIS diagnosis
Any grade I DCIS
Any grade II DCIS without comedonecrosis
Male DCIS
Grade II DCIS with comedonecrosis
Papillary or micropapillary DCIS
No history of invasive breast cancer in  years prior to study registration other than the current diagnosis (prior ductal breast carcinoma in situ [DCIS] at any time is acceptable)
Documentation of mammogram and ultrasound (including ductal carcinoma in situ [DCIS] and invasive cancer) of the diseased breast performed within  days prior to registration; mammogram for the unaffected contralateral breast is required within  months prior to registration
DCIS or Stage I-III primary invasive carcinoma of the breast
History of ductal carcinoma in situ (DCIS), except for participants treated exclusively with mastectomy > years prior to diagnosis of current breast cancer
Breast cancer\r\n* Infiltrating ductal carcinoma or ductal carcinoma in situ (DCIS), stage T, T, and T =< . cm, N and M\r\n* Patients benefiting from high dose rate brachytherapy (HDR) as either as a boost or accelerated partial breast irradiation regimen
INCLUSION - TREATMENT: Pathologic review shows no evidence of residual disease in the tumor bed (to also include no evidence of residual ductal carcinoma in situ [DCIS])
Histologically confirmed invasive carcinoma or ductal carcinoma in situ (DCIS) of the breast
Operable DCIS, suitable for breast conserving surgery
Patients with a history of ipsilateral or contralateral ductal carcinoma in situ (DCIS) are eligible
Ductal breast carcinoma in situ (DCIS) only
Ductal carcinoma in situ (DCIS) or invasive epithelial (ductal, medullary, papillary, mucinous [colloid], or tubular histologies)
Multicentric gross breast carcinoma (either DCIS or invasive cancer) or microscopic breast carcinoma occupying a volume with maximum dimensions of more than  centimeters
Clinical TNM invasive carcinoma or ductal carcinoma in situ (DCIS) < or equal to  cm
HER-+ (HER status is not required for women diagnosed with DCIS)
Proven multicentric carcinoma (invasive or ductal carcinoma in situ [DCIS]) in more than one quadrant or separated by >  centimeters
Subjects with histologically-confirmed operable invasive breast cancer or ductal carcinoma in situ (DCIS), who undergo core needle biopsy with a plan of surgical excision (goal: approximately  weeks of study medications after enrollment)
Pure DCIS
Breast cancers with an extensive in-situ ductal component (defined as >= % of the tumor volume and DCIS present within and in the surrounding normal breast tissue of the invasive tumor)
Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or two or more breast cancers not resectable through a single lumpectomy incision
On histological examination, the tumor must be ductal carcinoma in situ (DCIS) or invasive adenocarcinoma of the breast
Surgical treatment of the breast must have been lumpectomy; the margins of the resected specimen must be histologically free of tumor (DCIS and invasive); reexcision of surgical margins is permitted
Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by  or more centimeters
DCIS diagnosed with core biopsy
Prior history of invasive breast cancer or ductal breast carcinoma in situ (DCIS)
DCIS with focal invasion
Study participants must be cTc - cTa-d any N, M; any T is allowed if node positive (biopsy proven and HER positive) including no primary invasive cancer or only ductal breast carcinoma in situ (DCIS); metastatic workup is not required
Ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS) or breast conserving treatment and hormonal therapy for DCIS or invasive breast cancer
On histologic examination, the tumor must be ductal carcinoma in situ (DCIS) and/or invasive breast carcinoma
Prior history of DCIS or invasive breast cancer
Multicentric carcinoma (DCIS or invasive)
No prior surgical excision in the index breast for current DCIS diagnosis of DCIS
The participant has breast biopsy consistent with ductal carcinoma in situ (DCIS)
Patients with a prior diagnosis of contralateral ductal carcinoma in situ (DCIS) are eligible if they underwent a mastectomy or lumpectomy with whole breast radiation; prior partial breast irradiation, including brachytherapy, is not allowed; patients with a prior diagnosis of ipsilateral DCIS or invasive breast cancer who received radiation to that breast are not eligible
Subjects with ductal carcinoma in situ (DCIS)  that express HER- on % of the DCIS that have not had definitive surgery are diagnosed by core biopsy or needle-localized (NL) surgical biopsy with positive margins
Pathologically proven diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer
Grade - invasive ductal, mammary, mucinous, tubular, colloidal, or pure ductal carcinoma in situ (DCIS) measuring =< . cm on final pathology (the tumor should be clinical stage TNM in patients electing brachytherapy in whom the catheter will be placed intraoperatively)
Proven multicentric carcinoma (DCIS or invasive) in more than one quadrant or separated by  or more centimeters or diffuse (>  quadrant) suspicious calcifications
Patients with a hormone receptor-positive, HER-negative invasive cancer that meets study criteria may have ductal carcinoma in situ in another quadrant of the same breast or in the contralateral breast even if the DCIS is hormone receptor-negative
History of DCIS and/or lobular CIS (LCIS) that was treated with any form of systemic chemotherapy, hormonal therapy, or RT to the ipsilateral breast where invasive cancer subsequently developed. Participants who had their DCIS/LCIS treated with surgery only and/or contralateral DCIS treated with radiation are allowed to enter the study
Histologically-confirmed ductal carcinoma in situ (DCIS) or stage I-III invasive carcinoma of the breast; NOTE: women with history of breast cancer, radiation, or plastic surgery to the contralateral breast, or concurrent bilateral breast cancer, will not participate in the FNA portion of the study
Patients with a history of ipsilateral DCIS are eligible if they were treated with wide-excision alone, without radiation therapy; patients with a history of contralateral DCIS are not eligible
Subjects with DCIS with microinvasion
Patients may have had prior non-invasive (ductal carcinoma in situ [DCIS]) cancer if there has been no recurrence; prior ipsilateral invasive cancer also allowed if more than  years previous
Ductal carcinoma in situ (DCIS) or invasive ductal, medullary, papillary, mucinous (colloid), or tubular histologies
For patients with invasive breast cancer, pathologic N stage of N, N (i-), or N (i+); pathologic staging of the axilla is not required for patients with pure DCIS
Subjects who received radiotherapy for DCIS may enroll
ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone, or
Synchronous bilateral breast cancer (invasive or ductal carcinoma in situ [DCIS])
Ductal carcinoma in situ (DCIS) or Stage I-III, primary invasive carcinoma of the breast
Patients with history of breast cancer greater than  years from initial diagnosis and are disease free are eligible for the study; patients with history of ductal carcinoma in situ (DCIS) are eligible if there were treated with surgery alone
Diagnosis of ductal carcinoma in situ (DCIS) or stage I, II, or III breast cancer
DCIS prior to index lesion or history of progressive/recurrent DCIS after treatment
Participants who have been diagnosed with ductal carcinoma in-situ (DCIS) or invasive breast cancer and have been offered lumpectomy or mastectomy for surgical treatment will be considered for the study
Ductal carcinoma in situ (DCIS) diagnosis
Ambulatory outpatients with breast (including ductal carcinoma in situ [DCIS]) cancer
Presence of a proportion of ductal carcinoma in situ (DCIS) in the core biopsy specimen which is compatible with extensive intraductal component (EIC)
Invasive or ductal carcinoma in situ (DCIS) breast cancer
Patient has diagnosis of biopsy-proven primary breast cancer or a diagnosis of pure ductal carcinoma in situ (DCIS) who will be undergoing intraoperative lymphatic mapping as part of their standard surgical plan
Prior breast cancer or DCIS diagnosis
Previous treatment for breast cancer including chemotherapy, endocrine therapy and radiotherapy; women with prior ductal breast carcinoma in situ (DCIS) who were treated with surgery only and whose treatment ended >=  years prior to enrollment are eligible for the trial
Women with a previous history of invasive breast cancer or bilateral ductal carcinoma in situ (DCIS) or current untreated DCIS; women with a history of cancer within the last  years, except for non-melanoma skin cancer; women with unilateral DCIS (with or without radiation therapy) are eligible as long as they have an unaffected breast
History of prior ductal carcinoma in situ (DCIS) treated within the past two years; patients completing all treatment for a previous diagnosis of DCIS over two years prior to the current diagnosis are eligible
Histologically confirmed invasive breast cancer or Ductal Carcinoma In Situ (DCIS)
History of any of the following:\r\n* Invasive breast cancer\r\n* Ductal breast carcinoma in situ (DCIS)\r\n* Flat epithelial atypia
DCIS or previous invasive ductal carcinoma.
Positive margins on ink after definitive surgery either for ductal carcinoma in situ (DCIS) or invasive cancer
Any personal history of cancer, including ductal carcinoma in situ (DCIS) and not including non-melanoma skin cancers
No patients with previous ipsilateral or contralateral invasive breast cancer or ductal carcinoma in situ (DCIS)
Personal history and/or concomitant diagnosis of invasive breast cancer or DCIS
Core needle biopsy positive for invasive breast cancer or ductal breast carcinoma in situ (DCIS)
Previous surgery for DCIS or invasive cancer
History of other malignancy in the past  years except non-melanomatous skin cancer, breast ductal carcinoma in situ (DCIS) and low-risk prostate adenocarcinoma
History of other malignancy in the past  years except non-melanomatous skin cancer, breast ductal carcinoma in situ (DCIS) and low-risk prostate adenocarcinoma
Women undergoing preoperative evaluation at the University of Kansas Cancer Center (KUCC) for a new diagnosis of breast cancer (ductal carcinoma in situ [DCIS] or any invasive breast cancer)
Patient's most recent surgery was wide local excision with or without re-excision and for which there was obtained clear (>=  mm) margins at breast conserving surgery, and the pathology reveals pure DCIS; patients with invasive cancer or DCIS with microinvasion will not be registered on step , but will be followed for clinical outcomes\r\n* NOTE: if resection is documented to have reached pectoral fascia and deep margin is free but less than  mm, the patient is eligible\r\n* NOTE: if no residual DCIS is found on wide local excision as it was fully removed in core biopsy, the patient is eligible\r\n* NOTE: patients with lobular carcinoma in situ (LCIS) as well as DCIS are eligible
Subjects with a diagnosis of primary breast cancer or subjects with pure ductal carcinoma in situ (DCIS).
Diagnosed with incident, primary, invasive, ductal or lobular, or other epithelial malignancy, clinical stage I or II, ER positive or negative breast cancer, or ductal carcinoma in situ (DCIS)
Histologically or cytologically confirmed primary invasive breast cancer, ductal carcinoma in situ (DCIS) or a combination of invasive breast cancer and DCIS. Subjects who had diagnostic surgical biopsies are excluded from participation.
DCIS must be >=  mm of DCIS on one single core; can be <  mm if DCIS is identified on multiple cores (at least  cores)
Women presenting after excision with positive margins are eligible; Ki-, cyclooxygenase  (Cox-), cyclin-dependent kinase inhibitor A (P-), expression in immediately adjacent tissue is similar to what is found in DCIS\r\n* Note: Positive margins are defined as DCIS present at the inked margin or DCIS <  mm from the margin
